Corvus Pharmaceuticals, Inc. (CRVS) Misses Q3 EPS by 49c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of ($0.60), $0.49 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• San Francisco Hoarding Cleanup Expands Hoarding Cleanup and Property Cleanout Services Across the Bay Area
• White House: barrels from Venezuela deal could hit reserves in U.S. In November